HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb |
| |
| Authors: | Cesare Sarrecchia Alessandra Cappelli Pasquale Aiello |
| |
| Affiliation: | (1) Università di Roma “Tor Vergata”, Dipartimento di Sanità Pubblica, Via dei Giornalisti 15, 00135 Rome, Italy;(2) U:O.C. II Medicine, Hospital S. Eugenio, ASL RMC, Rome, Italy;(3) Infectious Diseases of University of Rome “Tor Vergata”, Rome, Italy |
| |
| Abstract: | A 51-year-old man who was hepatitis B surface antigen (HBsAg)-negative and positive for anti-hepatitisB surface antigen (anti-HBs) and anti-hepatitis B core antigen (anti-HBc), during rituximab therapy for chronic Lymphocytic leukemia, developed reactivation of hepatitisB virus (HBV) infection with hepatitis that proceededtowards hepatic failure and death in spite of lamivudine therapy. HBsAg remained persistently negative, notwithstanding a high HBV-DNA titer. Our observation, following other cases of fatal reactivation of HBV infection in patients receiving rituximab, suggests that, in all patients with previous markers of HBV infection, lamivudine prophylaxis should be considered during rituximab therapy. |
| |
| Keywords: | Rituximab Lamivudine Hepatitis B virus Leukemia |
| 本文献已被 SpringerLink 等数据库收录！ |
|
